Ikuo Tsunoda
Ikuo Tsunoda is an expert in Immunology at Kindai University (Japan). Ikuo Tsunoda has authored 140 publications, the most recent in 2026. SLR score: 437 (community average: 125). How the SLR is computed.
LeadR Profile
Immunology
Subspecialties: Oncology - Biochemistry - Veterinary Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Ikuo Tsunoda obtained his MD and PhD degrees from Tohoku University School of Medicine, Sendai, Japan. He continued his research on multiple sclerosis (MS) as a Research Associate at Tohoku University School of Medicine. He trained as a Neurology resident for 2 years under Teiji Yamamoto, MD, Professor at Fukushima Medical University. He also trained in neuropathology under Yuzo Iwasaki, MD, PhD, Professor, at Tohoku University School of Medicine. In 1995, he started working at the Department of Neurology, University of Utah, as a Postdoctoral fellow in Dr. Robert S. Fujinami’s laboratory. At the University of Utah, he was offered a position as a Research Associate in 1999, an Instructor in 2002, and an Assistant Professor in 2005 in the Department of Neurology, and moved to the Department of Pathology as an Assistant Professor in 2007. In 2009, he relocated his laboratory to the Department of Microbiology and Immunology at the Louisiana State University Health Sciences Center at Shreveport as an Assistant Professor. In 2015, he was promoted to Associate Professor. He has been certified by the Educational Commission for Foreign Medical Graduates (ECFMG)in the US. In 2016, he relocated his laboratory to Japan and became Professor and Chair at the Department of Microbiology, Kindai (Kinki) University Faculty of Medicine, Osaka. His research topics mainly include experimental autoimmune encephalomyelitis, HPV vaccines, Theiler’s murine encephalomyelitis virus (TMEV), and microbiota.
Organizations
Career arc: 1994 - 2026
Number : 140
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Long-term CT and US imaging of canine prostatic carcinoma after prostatic artery embolization: a 900-day follow-up case report. PMID 42866543 — microspheres, prostate, arteries, prostatic neoplasms, therapeutics, wounds and injuries, endovascular procedures | Front Vet Sci | 2026 | 0 |
| Towards Global HPV Eradication: Single-Dose HPV Vaccination vs. Pseudoscience. PMID 42029552 — safety, poliomyelitis, vaccines, uterine cervical neoplasms, neoplasms, vaccination, autoimmune diseases, alphapapillomavirus, vaccination hesitancy, human papillomavirus viruses | Pathophysiology | 2026 | 0 |
| The Safety of Alcaligenes Lipid A in a Virus-Induced Immune Disease Model Associated with IgA, Th17 Cells, and Microbiota. PMID 41754498 — cells, lipid a, safety, immunohistochemistry, vaccines, virology, alcaligenes, vaccination, immunoglobulin a, immune system diseases, viruses, autoimmune diseases, th17 cells, bacteria, microbiota | Viruses | 2026 | 0 |
| Lack of molecular mimicry between HPV vaccine L1 antigen and human proteins by a computational analysis. PMID 41507632 — autoantibodies, respiratory syncytial viruses, epitopes, leukocyte l1 antigen complex, vaccines, antibodies, molecular mimicry, neoplasms, vaccination, drug-related side effects and adverse reactions, viruses, alphapapillomavirus, human papillomavirus viruses | Int J Clin Oncol | 2026 | 2 |
| Flavivirus-based bivalent nanoparticle vaccines induce neutralizing antibodies and Th1 responses against flavivirus and coupling antigens. PMID 41210957 — parvovirus b19, human, sars-cov-2, vaccines, parvovirus, antibodies, nanoparticles, antibodies, neutralizing, viruses, natural science disciplines, flavivirus, nanovaccines | iScience | 2025 | 0 |
LeadR Networks
Main global connection map